Tel:
Hubei Vanz Pharm Co.,ltd
Hubei Vanz Pharm Co.,ltd

Warrantable quality,Trustable service!

Home ProductsActive Pharmaceutical Ingredient

Api Pharmaceutical Raw Material Lapatinib Ditosylate CAS 231277-92-2

Api Pharmaceutical Raw Material Lapatinib Ditosylate CAS 231277-92-2

  • Api Pharmaceutical Raw Material Lapatinib Ditosylate CAS 231277-92-2
  • Api Pharmaceutical Raw Material Lapatinib Ditosylate CAS 231277-92-2
Api Pharmaceutical Raw Material Lapatinib Ditosylate CAS 231277-92-2
Product Details:
Place of Origin: China
Brand Name: Vanz
Certification: ISO9001
Model Number: 231277-92-2
Payment & Shipping Terms:
Minimum Order Quantity: 1g
Packaging Details: bags or drum
Delivery Time: 3-5 days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 2kg per month
Contact Now
Detailed Product Description
Name: Lapatinib / Lapatinib Ditosylate CAS: 231277-92-2
Appearance: Yellow Fine Powder COA: Available
Assay: 99%min Stock: Available
High Light:

active pharmaceuticals ingredients

,

active pharma ingredients

Api Pharmaceutical Raw Material Lapatinib Ditosylate CAS 231277-92-2

 

Introduction

 

Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours.[1] It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.[2] It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).

 

Synonym: lapatinib;n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-;Lapatinib(TINIBS);N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;Lapatinib Base N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
Application: An inhibitor of Src family kinases, including c-Abl and Bcr-Abl tyrosine kinase activity
CAS Number: 231277-92-2
Purity: ≥99%
Molecular Weight:  581.0575432
Molecular Formula: C29H26ClFN4O4S

 

Status

  • On March 13, 2007, the U.S. Food and Drug Administration (FDA) approved lapatinib in combination therapy for breast cancer patients already using capecitabine (Xeloda, Roche). In January 2010, Tykerb received accelerated approval for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is indicated.
  • Pharmaceutical company GlaxoSmithKline (GSK) markets the drug under the propriety names Tykerb (mostly US) and Tyverb (mostly Europe). The drug currently has approval for sale and clinical use in the US, Australia, Bahrain, Kuwait, Venezuela, Brazil,New Zealand,South Korea, Switzerland, Japan, Jordan, the European Union, Lebanon, India and Pakistan.
  • On the 2nd of August 2013, India's Intellectual Property Appellate Board revoked the patent for Glaxo's Tykerb citing its derivative status, while upholding at the same time the original patent granted for Lapatinib.
  • The drug lapatinib ditosylate is classified as S/NM (a synthetic compound showing competitive inhibition of the natural product) that is naturally derived or inspired substrate (Gordon M. Cragg, Paul G. Grothaus, and David J. Newman, Impact of Natural Products on Developing New Anti-Cancer Agents, Chem. Rev. 2009, 109, 3012–3043)

 

Related Intermediate

 

Lapatinib ditosylate 388082-78-8
4-Chloro-6-iodoquinazoline 98556-31-1
2-Formylfuran-5-boronic acid 27329-70-0
2-Aminoethylmethylsulfone hydrochloride 104458-24-4
N-[3-Chloro-4-(3-fluorobenzyloxy)
phenyl]-6-iodoquinazolin-4-amine
231278-20-9

 

FAQ


Q1: Are you a manufacturer ?

A: Yes, We manufacture bulk products in our factory located in Jiayu, Hubei, and produce small quantity and customer synthesis products in our lab located in Wuhan. But we also do some trading business.

Q2: What`s your delivery

A: We send goods in 3 working day after receiving your payment by DHL, FEDEX, TNT, EMS, AIR OR SEA as you request, usually you can find shipping details in 3 to 5 working days after your payment.

Q3: What certificates and documents do you offer?

A: Some technical paperwork is available, such as COA, HNMR, HPLC, LC-MS etc.

Q4: Why should I choose you?

A: Factory supply with the most compatitive price and high quality!!!

Q5: Can I get best price from you?

A: Of course. We don't chase excessive profits and always try tp give best offer. If you are good at bargaining, you can also enjoy fun of bargaining. Just don't make it too hard!

Q6: How should I pay?

A: We accept all kinds of payment ways. such as alibaba trade asssurance, T/T, West Union, Money Gram.

Q7: Do you provide free sample?

A: We can provide free sample of some chemicals and you just need you to cover the delivery cost.

Api Pharmaceutical Raw Material Lapatinib Ditosylate CAS 231277-92-2 0

Contact Details
Hubei Vanz Pharm Co.,ltd

Contact Person: Ms. Wendy Wang

Tel: +86 15927784577

Fax: 86-27-84492310

Send your inquiry directly to us
Hubei Vanz Pharm Co.,ltd
Room 2114, Jingkai future town, Longyang Road, Wuhan Economic & Technological Development District, Wuhan City, Hubei , China
Tel:86-27-84492310
Mobile Site Privacy PolicyChina active pharma ingredients Supplier. Copyright © 2016 - 2022 api-pharmaceuticals.com. All Rights Reserved. Developed by ECER